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BACKGROUND: The aim of this was to evaluate FDG-PET (2-(fluorine-18)-fluoro-2-deoxy-D-glucose positron emission tomography)
for assessment of residual tumour after primary chemotherapy of large and locally advanced breast cancer in comparison with
conventional imaging modalities.
METHODS: In a prospective multicentre trial, 99 patients underwent one or more breast imaging modalities before surgery in addition
to clinical examination, namely, FDG-PET (n¼89), mammography (n¼47), ultrasound (n¼46), and magnetic resonance imaging
(MRI) (n¼46). The presence of residual tumour by conventional imaging, dichotomised as positive or negative, and the level of FDG
uptake (standardised uptake values, SUV) were compared with histopathology, which served as the reference standard. Patients with
no residual tumour or only small microscopic foci of residual tumour were classified as having minimal residual disease and those with
extensive microscopic and macroscopic residual tumour tissue were classified as having gross residual disease.
RESULTS: By applying a threshold SUV of 2.0, the sensitivity of FDG-PET for residual tumour was 32.9% (specificity, 87.5%) and
increased to 57.5% (specificity, 62.5%) at a threshold SUV of 1.5. Conventional imaging modalities were more sensitive in identifying
residual tumour, but had a low corresponding specificity; sensitivity and specificity were as follows: MRI 97.6 and 40.0%,
mammography 92.5 and 57.1%, ultrasound 92.0 and 37.5%, respectively. Breast MRI provided the highest accuracy (91.3%), whereas
FDG-PET had the lowest accuracy (42.7%).
CONCLUSIONS: FDG-PET does not provide an accurate assessment of residual tumour after primary chemotherapy of breast cancer.
Magnetic resonance imaging offers the highest sensitivity, but all imaging modalities have distinct limitations in the assessment of
residual tumour tissue when compared with histopathology.
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An increasing number of breast cancer patients are undergoing
pre-operative (neoadjuvant) chemotherapy regimens. Primary
systemic chemotherapy frequently reduces the tumour volume,
which increases the frequency of successful breast-conserving
surgery (van der Hage et al, 2001). Histopathology obtained from
breast surgery after completion of chemotherapy serves as the
reference standard for evaluation of residual tumour. Patients with
no residual invasive tumour have longer disease-free and overall
survival rates compared with patients with residual invasive
tumour (Feldman et al, 1986; Machiavelli et al, 1998; Kuerer
et al, 1999; Wolmark et al, 2001; Valero et al, 2002). However, only
B10–25% of breast cancer patients achieve a histopathological
complete response after primary systemic therapy (Bonadonna
et al, 1998; Fisher et al, 2002; Bear et al, 2006). Other
histopathological response classifications combine patients with
no residual tumour and those with only small microscopic foci of
residual tumour as minimal residual disease (MRD) compared
with gross residual disease (GRD), which is defined as extensive
residual microscopic or macroscopic tumour.
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sThe accurate pre-operative assessment of residual tumour is
important for guiding the surgical approach to ensure negative
resection margins and to minimise morbidity. Different response
patterns of primary breast tumours have to be taken into account,
as some shrink concentrically to a solitary residual mass, whereas
others leave scattered microscopic or macroscopic tumours within
the tumour bed (Abraham et al, 1996; Partridge et al, 2002).
Surgery focussing on the residual mass carries a higher risk of
leaving microscopic tumour tissue behind, which may necessitate
further surgical interventions or predispose to local recurrences.
Conversely, tumours with a pathological complete response (pCR)
may have unnecessary large resections of the tumour bed.
Therefore, clinical examinations, as well as mammography,
ultrasound, and magnetic resonance imaging (MRI), are often
used to evaluate the presence and the extent of residual tumour. It
has been suggested that positron emission tomography (PET)
using the radiolabelled glucose analogue 2-(fluorine-18)-fluoro-2-
deoxy-D-glucose (FDG) can be used to assess the extent and
localisation of tumour deposits for a large variety of tumours,
including breast cancer (Avril et al, 2000; Fletcher et al, 2008;
Mahner et al, 2008). In lymphoma patients, FDG-PET has been
recommended for routine post-treatment assessment, particularly
for the differentiation between viable tumour and fibrosis and
scarring in residual masses (Juweid et al, 2007).
The role of imaging modalities for post-chemotherapy assess-
ment of primary breast cancers still needs to be defined. Breast
ultrasound, mammography, and clinical examination tend to
overestimate the residual tumour volume because of chemother-
apy-induced necrosis and fibrosis (Yeh et al, 2005). Magnetic
resonance imaging of the breast has been shown to be a sensitive
method for visualisation of residual tumour, but the negative
predictive value seems to be limited (Abraham et al, 1996; Rieber
et al, 2002; Wasser et al, 2003; Denis et al, 2004; Warren et al, 2004;
Belli et al, 2006; Segara et al, 2007). There is little information
available on the potential role of FDG-PET in the assessment of
residual breast cancer following primary chemotherapy.
The aim of our prospective multicentre study was to evaluate
FDG-PET for monitoring primary chemotherapy in newly
diagnosed large (X3cm) or locally advanced breast cancer.
Patients underwent FDG-PET at baseline, after the first and second
cycle of chemotherapy and before surgery. We have recently
reported our findings regarding the ability of early changes in
tumour glucose metabolism to predict treatment response
(Schwarz-Dose et al, 2009). In a previous publication, we analysed
relative changes in tumour FDG uptake early in the course of
neoadjuvant chemotherapy and compared the derived early
metabolic tumour response with histopathological response after
the completion of chemotherapy (Schwarz-Dose et al, 2009).
The analysis presented in this paper is distinctly different, as it
addresses the role of FDG-PET for assessment of residual tumour
after completion of pre-operative chemotherapy in comparison
with conventional breast imaging modalities (mammography,
ultrasound, MRI) and clinical examination. The presence of
residual tumour, dichotomised as positive or negative, and the
level of FDG uptake (standardised uptake values, SUV) were com-
pared with histopathology, which served as the reference standard.
In addition, the size of residual tumour measured by means of
conventional breast imaging and assessed by clinical examination
was compared with the size obtained from histopathology.
MATERIALS AND METHODS
Patients
Patients with newly diagnosed large (X3cm) or locally
advanced (UICC Stage III) non-inflammatory breast cancer, who
participated in a prospective, randomised, multicentre trial
comparing two regimens of pre-operative chemotherapy
(epirubicin and paclitaxel either as standard dose (ET) or dose
dense sequential regimen (EP) plus adjuvant cyclophosphamide,
methotrexate, and fluorouracil (CMF)), were eligible for a
prospective FDG-PET treatment monitoring study (Schwarz-Dose
et al, 2009; Untch et al, 2009).
The Universita ¨tsklinikum Hamburg-Eppendorf (UKE), the
Ludwig Maximillians Universita ¨tM u ¨nchen (LMU), and the
Technische Universita ¨tM u ¨nchen (TUM) participated in the
FDG-PET study. In these three study centres, 173 patients were
recruited into the ET/CMF trial, of whom 104 patients participated
in the FDG-PET study. A total of 99 patients had one or more
imaging modalities, either FDG-PET, mammography, breast
ultrasound, or MRI for pre-operative assessment of residual
tumour tissue. Detailed patient characteristics are given in
Table 1.
Patients with known diabetes mellitus were not included, in
addition to those falling under the exclusion criteria defined for
the ET/CMF chemotherapy trial. The study protocol prospectively
defined the technical parameters, including timing for FDG-PET
Table 1 Patient characteristics (n¼99)
Age (years)
Median 50
Range 30–66
Menopausal status (n)
Premenopausal 49
Postmenopausal 50
cT before chemotherapy (n)
T2 39
T3 42
T4 15
Tx 3
cN before chemotherapy (n)
N0 22
N1 56
N2 11
Nx 10
Estrogen receptor status (n)
Positive 61
Negative 32
Not available 6
Histology (n)
Invasive ductal 87
Invasive lobular 11
Invasive medullary 1
Grading (n)
G2 52
G3 45
Not available 2
Chemotherapy (n)
ET regimen 55
EP regimen 44
Residual disease after chemotherapy (n)
Minimal residual disease 17
Gross residual disease 82
Abbreviations: ET regimen¼epirubicin and paclitaxel; cT¼clinical tumour stage
according to TNM classification; cN¼clinical lymph node status according to TNM
classification; EP¼3 cycles epirubicin followed by 3 cycles paclitaxel at intervals of 2
weeks; ET¼4 cycles of combined epirubicin plus paclitaxel at intervals of 3 weeks.
Imaging residual breast cancer
J Schwarz-Dose et al
36
British Journal of Cancer (2010) 102(1), 35–41 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
simaging and criteria for anatomical and PET image analysis for the
participating centres before initiation of the study.
Details of the ET/CMF trial and the option to participate in the
evaluation of functional FDG-PET imaging were explained by a
gynaecological oncologist and by a nuclear medicine physician.
Written informed consent was obtained from all patients. Patients
who refused participation in the evaluation of FDG-PET were still
eligible for the ET/CMF trial. The study protocol was approved by
the local ethical committees of the University Hospitals in Munich
and Hamburg. The evaluation of FDG-PET for pre-operative
assessment of residual tumour tissue was funded by the Deutsche
Krebshilfe.
Neoadjuvant (pre-operative) chemotherapy
The ET/CMF trial compared two regimens: epirubicin plus
paclitaxel standard dose and dose dense sequential regimen. The
standard dose regimen (ET) consisted of four cycles of epirubicin
(90mgm
 2) and paclitaxel (175mgm
 2), given every 3 weeks. The
ET dose dense sequential consisted of three cycles of chemother-
apy with epirubicin (150mgm
 2) every 2 weeks, followed by three
cycles of paclitaxel (250mgm
 2) every 2 weeks, in combination
with G-CSF (filgrastim). After completion of chemotherapy, all
patients underwent breast-conserving surgery or mastectomy.
Assessment of histopathological residual tumour
Histopathological response was determined as previously de-
scribed by Honkoop et al (1998). Surgical specimens were cut into
0.5cm-thick slices and evaluated for the presence of macroscopic
tumour. Representative samples were taken from all areas of
macroscopically visible tumour and resection margins, as well as
from areas with marked fibrosis or scarring. All sections were
microscopically analysed for the presence of residual tumour.
Immunohistochemical staining with antibodies against cytoker-
atins was performed on selected sections to identify or verify
tumour residues. Complete response (pCR) required additional
sampling from macroscopically suspicious and uninvolved areas of
the surgical specimens. In addition, the ‘tumour bed’ was
identified by signs of tumour regression, such as necrosis,
presence of macrophages, or marked fibrosis. Specimens with no
residual invasive tumour were classified as having complete
histopathological response (pCR). Specimens with only few
scattered foci of microscopic residual invasive tumour (p2mm)
were classified as having minimal residual disease (pMRD). For the
purpose of this analysis, pCR and MRD were summarised in a
response category MRD. Gross residual disease comprised
tumours showing macroscopic residual tumour or extensive
residual tumour infiltration on microscopic examination. The
presence of residual ductal in situ carcinoma did not influence the
histopathological response assessment.
FDG-PET imaging
Patients fasted for at least 6h before injection of 280–420MBq
(B10mCi) F-18 FDG. The mean blood glucose level was
101.7±13.6mg per 100ml. After an uptake period of 45min,
patients were positioned prone, with both arms at their sides on
the scanner couch. A gap in the scanner support ensured no
(deformation) compression of the breast. Whole-body PET
scanners (ECAT951R/31 (TUM), ECATExact47 (UKE), and
ECATExactHRþ (LMU); Siemens, Knoxville, TN, USA) were
used. Emission scans of the breast (2D mode), acquired in one bed
position, were obtained from 45 to 60min after tracer injection,
followed by a transmission scan with germanium-68 rod sources.
Emission data were corrected for random events, dead time, and
attenuation; image pixel counts were calibrated to activity–
concentration (Bqml
 1) and decay was corrected using the time
of tracer injection as reference.
Regions of interest (ROIs) were placed semi-automatically in
attenuation-corrected images. The tumour was first identified on
pre-treatment FDG-PET and subsequently an ROI was placed in
the tumour bed on post-treatment FDG-PET. The slice with the
highest radioactivity concentration within the tumour was
identified and a circular ROI with a diameter of 1.0cm was placed
in this area and in the directly adjacent slices. Standardised uptake
values were calculated using the average (SUVmean) and maxi-
mum (SUVmax) activity values within the ROIs, normalised to the
injected activity and patient’s body weight. Analysis of PET scans
was performed without knowledge of the results of other clinical
studies.
FDG-PET results were obtained for two SUV thresholds: SUV 2.0
and SUV 1.5. A positive PET result was defined as an SUV equal to
and above the threshold level. A negative PET result was defined as
an SUV below the threshold level. Histopathology served as
reference standard, as described above.
To assess a potential influence of the timing of FDG-PET
imaging after completion of chemotherapy, the mean and standard
deviations were compared for SUVs obtained before and after 7,
14, 21, and 28 days after the last day of chemotherapy.
Conventional breast imaging
After completion of primary chemotherapy and before surgery, the
study protocol of the ET/CMF trial included at least one conven-
tional imaging procedure, namely, mammography, breast ultra-
sound, and/or MRI. Investigations were performed in the same
manner as routine clinical imaging procedures and were analysed
by experienced radiologists. The results were dichotomised as
positive or negative for the presence of residual tumour. In the
case of a positive result, the lesions were measured in at least two
dimensions. These data were documented in the case record form
at the time of imaging and no retrospective analysis has been
performed.
In brief, for mammographic assessment, cranio-caudal and
lateral-oblique views of both breasts were acquired, with additional
compression and lateral views as required. Identified lesions were
measured in bi-directional maximum dimension. Ultrasound was
performed of all four quadrants of the breast. For MRI, multi-
sequence and multiplanar images of both breasts were obtained
before and after administration of intravenous contrast using
appropriate breast coils. The maximum length of enhancing
lesions was measured in transverse, coronal, and sagittal planes.
Physical examination of the breast
All patients were assessed by physical examination by the
gynaecological oncologist before surgery. The tumour-involved
breast was assessed by palpation. In concordance with anatomical
imaging, results were dichotomised as positive or negative for the
presence of residual tumour.
Statistical analysis
Data collection was centralised in one study centre (UKE). The
detection of residual tumour by physical examination, conven-
tional imaging or the level of FDG uptake above the threshold SUV
was defined as a positive test result. Histopathological evaluation
of residual tumour served as the reference, and the rate of true and
false positive test results, as well as the sensitivity, specificity, and
positive and negative predictive values were calculated accord-
ingly. The Mann–Whitney test was used to compare quantitative
parameters between groups of patients. Spearman’s rank correla-
tion coefficient (r) was used to describe correlations between
quantitative parameters. Quantitative parameters are expressed as
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smean±one standard deviation (s.d.). All statistical tests were
performed two-sided at a 5% level of significance.
RESULTS
A total of 99 out of 104 patients who participated in the FDG-PET
monitoring study had at least one imaging procedure after
completion of chemotherapy before surgery, in addition to
clinical examination, namely, FDG-PET (n¼89), mammography
(n¼47), ultrasound (n¼46), and MRI (n¼46). A total of 17
patients had MRD and 82 patients showed GRD on histopatho-
logical assessment. Out of 17 patients with MRD, two had
initially positive margins after surgery; one achieved tumour-
free margins after a second resection, and the other patient
underwent mastectomy due to extensive ductal in situ carcinoma
(DCIS). Five patients with MRD underwent mastectomy:
two patients due to extensive DCIS, one due to a large residual
mass at the time of surgery, and two on the basis of
patient preference.
FDG-PET imaging
In all, 89 patients underwent pre-operative FDG-PET imaging of
the breast. Standardised uptake values calculated for maximum
and average activity values within a tumour ROI showed a close
correlation (r¼0.91). The SUVmax was used for subsequent
analysis. Out of 89 patients, 16 (18.0%) had MRD and 73 patients
(82.0%) had GRD in histopathology. The mean of the SUVmax in
MRD was 1.4±0.7 compared with 1.8±0.9 in GRD. The difference
was statistically significant (P¼0.01).
We assessed two specific SUV thresholds for identifying
residual tumour. By applying a threshold SUV of 2.0, 26 FDG-
PET studies were positive (SUV X2.0) and 63 were negative
for residual tumour. However, 49 studies were false negative by
using this threshold, resulting in a sensitivity of 32.9% of
FDG-PET to detect residual tumour, with a corresponding
specificity of 87.5%. When applying a threshold SUV of 1.5,
the sensitivity to detect residual tumour increased to 57.5%
(specificity 62.5%).
We also assessed whether the level of FDG uptake was
influenced by the time interval between the last cycle of
chemotherapy and FDG-PET imaging. Pre-operative FDG-PET
imaging in all 89 patients was performed 16.4±6.4 days after the
last cycle of neoadjuvant chemotherapy, before surgery. The mean
SUV of all primary breast carcinomas after the last cycle of
chemotherapy was 1.7±0.9. There was no statistically significant
difference in the level of FDG uptake in patients who underwent
FDG-PET imaging within 7, 14, 21, or 28 days after completion of
chemotherapy (P40.3).
Mammography
A total of 47 patients underwent pre-operative mammography. Out
of these 47 patients, 7 (14.9%) had MRD and 40 patients (85.1%)
had GRD in histopathology. A total of 40 patients showed residual
tumour on mammography and 7 were negative for residual
tumour. The sensitivity of mammography to detect residual
tumour was 92.5% and specificity was 57.1%. Three mammo-
graphies were false positive, of which two cases showed masses of 1
and 2.5cm on mammography and no or MRD of less than 1mm in
histopathology. One patient had a residual mass of 8cm on
mammography and no residual invasive tumour but extensive in
situ carcinoma in the histopathological specimen. Mammography
was false negative in three cases, which histopathologically showed
residual invasive tumours between 2.5 and 7.5cm. The detailed
results are summarised in Table 2.
Breast ultrasound
A total of 58 patients underwent pre-operative breast ultrasound.
Out of 58 patients, 8 (13.8%) had MRD and 50 patients (86.2%)
had GRD in histopathology. A total of 51 breast ultrasound studies
were positive, of which five were false positive. Ultrasound of the
breast showed residual tumour masses between 0.4 and 3.3cm in
five patients who had no or MRD in histopathology. Only one of
these five false-positive cases had residual in situ carcinoma.
Breast ultrasound was true negative in three patients and false
negative in four cases, which histopathologically showed residual
ductal invasive carcinoma of 0.5 and 2.5cm in two cases and
residual lobular invasive carcinoma of 7.5cm in one case. The
sensitivity of the ultrasound to detect residual tumour was 92.0%,
with a corresponding specificity of 37.5%. When comparing
anatomical imaging modalities, the ultrasound had the highest rate
of false-positive results (62.5%) and the lowest overall accuracy
(89.7%) in detecting residual tumour after completion of
chemotherapy. The results are summarised in Table 2.
Breast MRI
A total of 46 patients underwent pre-operative MRI of the breast.
Of these 46 patients, 5 (10.9%) had MRD and 41 patients (89.1%)
had GRD in histopathology. In all, 43 breast MRI studies were
positive for residual tumour, of which three were false positive.
Table 2 Assessment of residual tumour after completion of primary systemic chemotherapy
Mammography
(n¼47)
Breast MRI
(n¼46)
Breast
ultrasound
(n¼58)
Physical
examination
(n¼99)
FDG-PET
threshold SUV
2.0 (n¼89)
FDG-PET
threshold
SUV 1.5 (n¼89)
Positive (n)4 0 4 3 5 1 8 32 6 4 8
Negative (n) 7 3 7 16 63 41
True positive (n)3 7 4 0 4 6 7 5 2 4 4 2
False positive (n)3 3 5 8 2 6
True negative (n)4 2 3 9 1 4 1 0
False negative (n)3 1 4 7 4 9 3 1
Sensitivity (%) 92.5 97.6 92.0 91.5 32.9 57.5
Specificity (%) 57.1 40.0 37.5 52.9 87.5 62.5
PPV (%) 92.5 93.0 90.2 90.4 92.3 87.5
NPV (%) 57.1 66.7 42.9 56.3 22.2 24.4
Accuracy (%) 87.2 91.3 84.5 84.8 42.7 58.4
Abbreviations: FDG-PET¼2-(fluorine-18)-fluoro-2-deoxy-D-glucose positron emission tomography; MRI¼magnetic resonance imaging; NPV¼negative predictive value;
PPV¼positive predictive value; SUV¼standardised uptake values. A positive imaging test result was defined as the detection of residual tumour. Histopathology served as
reference standard (minimal residual disease¼no residual tumour; gross residual disease¼residual tumour).
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sThese three patients showed residual masses between 0.4 and 2cm
on breast MRI and had no or MRD in histopathology. However,
two of these three patients had residual in situ carcinoma in
histopathology. One breast MRI study was false negative and had
residual ductal invasive carcinoma of 2.5cm in histopathology.
The breast MRI detected residual tumour with a sensitivity of
97.6% and a specificity of 40.0%. When comparing all imaging
modalities, MRI had the highest overall accuracy of 91.3% for
identifying residual tumour. The results are summarised in Table 2.
Tumour size assessed by conventional imaging vs
histopathology
The tumour size as assessed by mammography, breast MRI, and
breast ultrasound showed a low correlation with histopathological
tumour size (r-values 0.27, 0.43, and 0.50, respectively). Compar-
ing the different imaging modalities with each other showed a
reasonable correlation for mammography vs MRI (r¼0.83;
n¼20), mammography vs ultrasound (r¼0.78; n¼41), and
MRI vs ultrasound (r¼0.82; n¼24).
One patient with a residual tumour of 7.5cm, which was neither
detected by mammography nor by ultrasound, had a lobular
invasive carcinoma. Another patient who had a residual tumour of
2.5cm, which was not detected by mammography, ultrasound, or
MRI, had a ductal invasive carcinoma. In an additional eight
patients with lobular invasive carcinoma, residual tumour was
detected by either mammography, ultrasound, or MRI.
Physical examination of the breast
All 99 patients underwent a physical examination of the breast
before surgery. The presence or absence of residual tumour was
assessed by palpation. A total of 83 patients were positive for
residual tumour, of which 8 cases were false positive. These eight
patients were estimated to have residual tumours between 1 and
5cm by physical examination and showed no or MRD in
histopathology. Two of these eight patients had residual carcinoma
in situ. Physical breast examination was false negative in seven
patients, which histopathologically showed residual invasive
tumours between 2.5 and 7.5cm. The sensitivity and specificity
of the physical examination to detect residual tumour were 91.5
and 52.9%, respectively. When comparing all imaging modalities,
physical examination had the highest rate of false-negative results
(8.5%) in identifying residual tumour. The results are summarised
in Table 2.
DISCUSSION
Our prospective multicentre trial showed that breast MRI provided
the highest sensitivity (97.6%) for identifying residual tumour after
completion of primary chemotherapy compared with mammo-
graphy, ultrasound, and clinical examination. However, the
corresponding specificity for abnormal masses identified on MRI
was low (40%). Previous reports have suggested that breast MRI is
more accurate for assessment of residual tumour than conven-
tional imaging (Denis et al, 2004; Warren et al, 2004; Yeh et al,
2005; Bhattacharyya et al, 2008). Nevertheless, these studies also
revealed that MRI was prone to underestimate the extent of small
residual tumour in up to 39% of patients (Denis et al, 2004;
Warren et al, 2004; Yeh et al, 2005). This might partially be
explained by tumour regression with residual scattered viable
tumour cells within normal or necrotic tissue. In our study, MRI
was less accurate in predicting complete pathological response or
MRD with a negative predictive value of only 66.7%, which is an
important limitation. This underlines that surgery cannot be
obviated on the basis of results from imaging procedures. This is
in line with a previous report of 45 patients, in which microscopic
residual disease was found in 95% of patients who had a complete
response in breast MRI (Belli et al, 2006). A recent review of
evidence-based clinical applications for breast MRI suggested that
contrast-enhanced dynamic MRI might be more suitable for
differentiating between fibrosis and viable residual tumour
(DeMartini and Lehman, 2008). In addition, a comparison with
baseline MRI obtained before initiation of therapy might improve
the accuracy of assessing residual tumour.
When comparing conventional imaging modalities, ultrasound
had the highest rate of false-positive findings, with a specificity of
only 37.5%. A distinct limitation of mammography and breast
ultrasound is the differentiation between viable tumour and post-
treatment changes such as scarring and fibrosis when a residual
mass is present. Both extensive fibrosis and residual DCIS
accounted for the high rate of false-positive results in conventional
imaging, which ranged in our study between 42.9 and 62.5%.
We found a poor correlation between tumour sizes assessed by
pre-operative imaging compared with histopathological tumour
size. This is in contrast to previous reports, which found
correlation coefficients ranging from 0.70 to 0.98 for MRI
(Esserman et al, 1999; Partridge et al, 2002; Rosen et al, 2003;
Wasser et al, 2003; Martincich et al, 2004). However, a recent
retrospective review of neoadjuvant chemotherapy trials from the
MD Anderson Cancer Center also found a poor agreement between
tumour size measurements by mammography or ultrasound and
histopathology (Chagpar et al, 2006). The authors concluded that
there is no evidence that mammography or ultrasound performs
better than physical examination for measuring residual disease
after chemotherapy (Chagpar et al, 2006). In fact, the large
prospective trials of neoadjuvant chemotherapy to date, NSABP-18
and NSABP-27, have not incorporated imaging for assessing
residual tumour before surgery, but have relied on physical
examination (Wolmark et al, 2001; Bear et al, 2006). In our study,
physical examination of the breast before surgery was equally
effective for the detection of residual tumour with a sensitivity of
91.5% and a corresponding specificity of 52.9%.
An important aspect of primary systemic chemotherapy in
breast cancer is the low rate of complete pathological responses
ranging from 10 to 25% (Bonadonna et al, 1998; van der Hage et al,
2001; Fisher et al, 2002). In our study, 17 out of 99 patients (17%)
had MRD or a complete absence of tumour residues on
histopathological examination. The majority of patients (83%)
had GRD. This setting favours conventional imaging procedures,
which might in part explain sensitivities to detect residual masses
in the range of 90% for mammography, ultrasound, and MRI.
However, the limited specificity between 37.5% for breast
ultrasound and 57.1% for mammography reveals that there are
no specific criteria established for the further characterisation of
residual abnormalities as benign or malignant.
The metabolic activity of residual masses after systemic therapy,
assessed by FDG-PET, was found to be a clinically applicable
surrogate marker for treatment efficacy in a variety of settings.
However, a small series of breast cancer patients who had achieved
a good clinical response after primary chemotherapy revealed less-
promising results (Burcombe et al, 2002). None of the patients
presented with increased FDG uptake at the primary tumour site
before surgery, but 9 out of 10 patients had residual invasive
carcinoma on histopathology, ranging from 2 to 20mm in size. We
found a significantly lower FDG uptake after chemotherapy in
MRD (SUV 1.4±0.7) compared with GRD (SUV 1.8±0.9).
Subsequently, two defined thresholds of FDG uptake, SUV 41.5
and SUV 42.0, were assessed for identification of residual tumour.
FDG-PET provided the highest specificity among all imaging
modalities: 62.5% using a threshold SUV 41.5 and 87.5% for a
threshold SUV 42.0. By applying these criteria, the sensitivity was
only 32.9 and 57.5%, respectively. The low sensitivity could be
partially attributed to the limited spatial resolution of FDG-PET,
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swhich is in the range of 4–6mm. However, other factors such as
‘metabolic stunning’ of residual viable tumour tissue after
chemotherapy might have also contributed to the low detection
rate. It is noteworthy that we found no influence on the level of
FDG uptake depending on the time interval between the last cycle
of chemotherapy and FDG-PET imaging. According to the study
protocol, patients should undergo surgery within 4–6 weeks after
the last cycle of chemotherapy and only six patients had surgery
more than 28 days after chemotherapy. Response criteria
developed for lymphoma patients by an International Harmoniza-
tion Project (IHP) recommend a wait of 6–8 weeks after the last
cycle of chemotherapy to assess treatment response (Juweid et al,
2007). However, this would be difficult in the setting of primary
chemotherapy in breast cancer in which subsequent surgery is an
integral part of the multimodality treatment plan. Conversely, the
time interval between the last cycle of chemotherapy and surgery
might also affect histopathology findings, which serve as the
reference standard. One could hypothesise that prompt surgery
might identify histopathological residual tumour tissue, which is
already determined to undergo apoptosis and would not have been
detected at later time points. FDG-PET is frequently used with
great success for post-treatment assessment in the metastatic
setting, including in breast cancer (Mahner et al, 2008; Avril et al,
2009). The metabolic information from FDG-PET generally
provides a reliable marker of tumour viability and treatment
response, and has been validated in several trials using clinical
follow-up and survival as reference. Our results in the setting of
primary chemotherapy using histopathology as reference are to
some extent in contrast to these observations. The inability of
FDG-PET to identify small tumour deposits may have contributed
to the low accuracy of FDG-PET in our study.
In lymphoma, the level of FDG uptake after systemic therapy
was found to carry prognostic information (Spaepen et al, 2003;
Juweid et al, 2007). Whether metabolically inactive residual breast
cancer patients (42.5% of patients using a SUV threshold 41.5)
carry a better prognosis compared with patients with metabolically
active residual tumours remains to be determined. A comparison
of FDG-PET results with disease-free and overall survival is
required once outcome data become available to evaluate whether
FDG-PET may help to further stratify the group of patients with
residual disease after chemotherapy.
The question arises regarding the role of imaging procedures
after primary systemic therapy of primary breast cancer. Pre-
operative imaging would ideally provide the following information:
(i) accurate differentiation between responder and non-responder;
(ii) localisation and extent of residual tumour; and (iii) prognostic
information, for example, for further treatment stratification. We
showed that residual tumour size assessed after completion of
neoadjuvant chemotherapy by mammography, breast MRI, and
breast ultrasound showed only a weak correlation with histo-
pathological tumour size assessment. No current imaging modality
can exclude the presence of microscopic tumour residues; there-
fore, surgery and a subsequent histopathological evaluation of the
surgical specimen cannot be obviated. Thus, the main use of pre-
operative imaging is to guide surgical treatment planning. Com-
plete histopathological response (pCR) is defined as the absence of
invasive tumour and may therefore include patients with residual
DCIS. However, the presence of residual DCIS needs to be taken
into account while defining the extent of surgery, but DCIS cannot
be reliably identified and distinguished from regressive changes
either by conventional imaging or by FDG-PET. Health-care cost is
also an important consideration while applying imaging proce-
dures, although no convincing evidence exists as yet of their
benefits outside clinical trials. However, in a recent study, 84% out
of 31 patients were identified by MRI as potentially suitable
candidates for breast conservation after chemotherapy. Of them,
breast conservation was achieved in 90.5% and the low rate (9.5%)
of re-operation for positive resection margins indicates a potential
role of breast MRI in surgical treatment planning in selected cases
(Bhattacharyya et al, 2008).
Certain limitations of our study need to be taken into account.
Not all patients underwent all imaging procedures, as the study
protocol only included at least one conventional imaging
procedure at completion of chemotherapy before surgery. The
results were dichotomised as positive or negative for the presence
of residual tumour and one could have developed a more
sophisticated analysis. However, we believe that this approach
reduced the potential influence of multiple observers, which is
unavoidable in a prospective multicentre trial.
In conclusion, FDG-PET does not allow for an accurate assess-
ment of residual tumour after primary chemotherapy of breast
cancer. Magnetic resonance imaging offers the highest sensitivity,
but all imaging modalities have distinct limitations in the
assessment of residual tumour tissue when compared with
histopathology.
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